SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

Item

http://www.wikidata.org/entity/Q37475154

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

@en

SEOM Clinical Guideline for gastrointestinal sarcomas

@nl

type

Item

label

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

@en

SEOM Clinical Guideline for gastrointestinal sarcomas

@nl

prefLabel

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

@en

SEOM Clinical Guideline for gastrointestinal sarcomas

@nl

P1476

SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).

@en

P2093

A Estival

http://www.w3.org/2001/XMLSchema#string

A Poveda

http://www.w3.org/2001/XMLSchema#string

C Serrano

http://www.w3.org/2001/XMLSchema#string

D Vicente

http://www.w3.org/2001/XMLSchema#string

I Sevilla

http://www.w3.org/2001/XMLSchema#string

J Martin-Broto

http://www.w3.org/2001/XMLSchema#string

J Rubió

http://www.w3.org/2001/XMLSchema#string

M J Lecumberri

http://www.w3.org/2001/XMLSchema#string

R D de Beveridge

http://www.w3.org/2001/XMLSchema#string

V Martinez

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Gastrointestinal stromal tumours: origin and molecular oncology.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

P2888

s12094-016-1579-9

P304

1221-1228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-016-1579-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27896638

http://www.w3.org/2001/XMLSchema#string

P932

5138245

http://www.w3.org/2001/XMLSchema#string